Record Revenue Growth
iRhythm achieved a full-year 2024 revenue growth of over 20%, driven by sustained volume demand across all customer channels and a 24% year-over-year growth in Q4 2024, reaching $164.3 million.
Significant Account Openings
Record new account openings within long-term continuous monitoring and mobile cardiac telemetry, supported by strong demand from national value-based care entities.
International Expansion
Commercial launch of Zio services in Austria, the Netherlands, Switzerland, and Spain, with Japanese PMDA regulatory approval for Zio monitor achieved in 2024.
Gross Margin Improvement
Improved gross margin profile from 66% at the beginning of the year to 70% by Q4 2024.
Adjusted EBITDA Improvement
Adjusted EBITDA in Q4 2024 was $19.3 million or 11.7% of revenue, marking a significant improvement from a margin of 1.8% in Q4 2023.
Cash Flow Generation
iRhythm generated over $30 million in free cash flow during the last three quarters of 2024.